Intellia Therapeutics, Inc.

NTLA

Nasdaq; healthcare; SIC 2835, In Vitro & In Vivo Diagnostic Substances; CIK 0001652130

E

weakest fifth of 370 graded peers in healthcare

rank 320 of 370; percentile 86.4; sampling error 2.5 points; lower is stronger

A B C D E

E, the bear



Scoreboard	
Profitability	D percentile 77.2
Solvency	C percentile 49.1
Growth and financing	D percentile 62.9
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $842.1M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	short runway not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Feb 26, 2026 237 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$11.84 2026-10-20; market equity $1.7B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

Intellia Therapeutics, Inc. ("we," "us," "our," "Intellia," or the "Company") is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, we aim to reset the standard for medicine by durably treating the root causes of disease.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 77.2						
Gross profitability	not computable	32.3%				
latest aligned inputs end 2021-12-31; latest annual assets end 2025-12-31						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(1.8%)	(6.6%)	77.2	812	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 4					
Solvency, sleeve percentile 49.1					
Twelve-month failure probability	0.09%	0.06%	56.1	247	2026-06-30
Altman Z double-prime	(6.12)	(0.30)	55.0	757	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	5.08x	2.96x	36.1	840	2025-12-31
Growth and financing, sleeve percentile 62.9					
Revenue growth, three-year compound	9.1%	10.1%	52.8	414	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
a prior annual working-capital observation is required					
Asset growth, three years	(17.9%)	2.1%	80.0	705	2025-12-31
Net share issuance, one year	14.1%	2.4%	56.0	633	2026-02-13

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.7 months

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
315	Amgen Inc. (AMGN)	85.1	E	
316	Organon & Co. (OGN)	85.4	E	
317	Sonoma Pharmaceuticals, Inc. (SNOA)	85.6	E	dilution, fortress balance sheet
318	National Vision Holdings, Inc. (EYE)	85.9	E	
319	Natural Alternatives International Inc. (NAII)	86.2	E	dilution, late filer, fortress balance sheet
320	Intellia Therapeutics, Inc. (NTLA)	86.4	E	short runway
321	Outset Medical, Inc. (OM)	86.7	E	dilution
322	DarioHealth Corp. (DRIO)	87.0	E	dilution, short runway
323	Lexaria Bioscience Corp. (LEXX)	87.3	E	dilution, short runway
324	Heron Therapeutics, Inc. (HRTX)	87.5	E	distress
325	Bristol Myers Squibb Co. (BMY)	87.9	E	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(26.3%)	8.0%	26
Distance from 52-week high	(57.7%)	(29.7%)	20
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(23.9%)	(1.0%)	21
Book value to price	0.44	0.28	65
Sales to price	0.04	0.30	14
Composite equity issuance, five years	72.7%	20.5%	71
Relative strength against the sector, log excess return	(0.52)	(0.13)	26

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$106.1M
Operating cash flow, four quarters	-$346.6M
Months of runway	3.7
Days since last periodic filing	76 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$45.7M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$33.1M	2021-12-31	2024-02-22	10-K	24-018736
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$0	2021-12-31	2022-02-24	10-K	22-001981
3	assets	us-gaap:Assets	$1.3B	2021-12-31	2023-02-23	10-K	23-004097
4	net income	us-gaap:NetIncomeLoss	-$412.7M	2025-12-31	2026-02-26	10-K	26-076550
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$394.7M	2025-12-31	2026-02-26	10-K	26-076550
6	assets	us-gaap:Assets	$842.1M	2025-12-31	2026-02-26	10-K	26-076550
7	assets	us-gaap:Assets	$1.2B	2024-12-31	2026-02-26	10-K	26-076550
8	current assets	us-gaap:AssetsCurrent	$527.7M	2025-12-31	2026-02-26	10-K	26-076550
9	current liabilities	us-gaap:LiabilitiesCurrent	$103.9M	2025-12-31	2026-02-26	10-K	26-076550
10	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$2.6B	2025-12-31	2026-02-26	10-K	26-076550
11	operating income	us-gaap:OperatingIncomeLoss	-$441.0M	2025-12-31	2026-02-26	10-K	26-076550
12	book equity	us-gaap:StockholdersEquity	$671.4M	2025-12-31	2026-02-26	10-K	26-076550
13	liabilities	us-gaap:Liabilities	$170.7M	2025-12-31	2026-02-26	10-K	26-076550
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$67.7M	2025-12-31	2026-02-26	10-K	26-076550
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$57.9M	2024-12-31	2026-02-26	10-K	26-076550
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$36.3M	2023-12-31	2026-02-26	10-K	26-076550
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$52.1M	2022-12-31	2025-02-27	10-K	25-029007
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.1M	2025-12-31	2026-02-26	10-K	26-076550

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$348.9M	2024-12-31	2026-02-26	10-K	26-076550
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$5.8M	2024-12-31	2026-02-26	10-K	26-076550
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$394.1M	2023-12-31	2026-02-26	10-K	26-076550
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$14.0M	2023-12-31	2026-02-26	10-K	26-076550
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$333.3M	2022-12-31	2025-02-27	10-K	25-029007
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$13.6M	2022-12-31	2025-02-27	10-K	25-029007
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$6.2M	2016-12-31	2019-02-27	10-K	19-004680
26	depreciation amortization	us-gaap:Depreciation	$1.1M	2016-12-31	2018-03-14	10-K	18-005544
27	operating income	us-gaap:OperatingIncomeLoss	-$32.2M	2016-12-31	2019-02-27	10-K	19-004680
28	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$31.6M	2016-12-31	2018-03-14	10-K	18-005544
29	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2016-12-31	2017-03-14	10-K	17-082186
30	current assets	us-gaap:AssetsCurrent	$281.3M	2016-12-31	2018-03-14	10-K	18-005544
31	current liabilities	us-gaap:LiabilitiesCurrent	$30.7M	2016-12-31	2018-03-14	10-K	18-005544
32	assets	us-gaap:Assets	$1.3B	2023-12-31	2025-02-27	10-K	25-029007
33	assets	us-gaap:Assets	$1.5B	2022-12-31	2024-02-22	10-K	24-018736
34	shares outstanding	dei:EntityCommonStockSharesOutstanding	118,133,546	2026-02-13	2026-02-26	10-K	26-076550
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	103,517,460	2025-02-14	2025-02-27	10-K	25-029007

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.